Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals said late Monday it has completed enrollment in a phase 2b study of emricasan in approximately 330 patients with biopsy-confirmed nonalcoholic steatohepatitis and stage 1 to 3 fibrosis. The primary endpoint of the study is a biopsy-based improvement in fibrosis by at least one stage compared to placebo using NASH CRN without worsening of steatohepatitis. Secondary endpoints include resolution of steatohepatitis without worsening of fibrosis, nonalcoholic fatty liver […]

Read More ˃